Portage Biotech Inc. (PRTG)
USD 10.27
(-4.55%)
USD 10.27
(-4.55%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 18.19 Million USD | 9.79% |
| 2023 | 16.57 Million USD | 6.34% |
| 2022 | 15.58 Million USD | 25.31% |
| 2021 | 12.44 Million USD | 108.1% |
| 2020 | 5.97 Million USD | 116.28% |
| 2019 | 2.76 Million USD | 24.11% |
| 2018 | 2.22 Million USD | -93.73% |
| 2017 | 35.49 Million USD | 286.28% |
| 2016 | 9.18 Million USD | 112.83% |
| 2015 | 4.31 Million USD | 54.76% |
| 2014 | 2.78 Million USD | 125.84% |
| 2013 | 1.23 Million USD | -26.79% |
| 2012 | 1.68 Million USD | -51.62% |
| 2011 | 3.48 Million USD | 6.35% |
| 2010 | 3.27 Million USD | 511.53% |
| 2009 | 536.13 Thousand USD | -26.43% |
| 2008 | 728.73 Thousand USD | 8.04% |
| 2007 | 674.53 Thousand USD | -69.35% |
| 2006 | 2.2 Million USD | -49.53% |
| 2005 | 4.35 Million USD | 307.1% |
| 2004 | 1.07 Million USD | 371.79% |
| 2003 | 226.98 Thousand USD | -68.08% |
| 2002 | 711.15 Thousand USD | 61.51% |
| 2001 | 440.31 Thousand USD | 1967.31% |
| 2000 | 21.29 Thousand USD | -93.27% |
| 1999 | 316.47 Thousand USD | -18.77% |
| 1998 | 389.59 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 18.19 Million USD | 9.79% |
| 2024 Q1 | 5 Million USD | 22.87% |
| 2024 Q4 | 3.24 Million USD | -19.33% |
| 2024 Q3 | 4.02 Million USD | -32.3% |
| 2024 Q2 | 5.94 Million USD | 18.71% |
| 2023 Q2 | 3.65 Million USD | -10.62% |
| 2023 Q4 | 4.07 Million USD | -14.37% |
| 2023 FY | 16.57 Million USD | 6.34% |
| 2023 Q1 | 4.08 Million USD | -9.1% |
| 2023 Q3 | 4.76 Million USD | 30.3% |
| 2022 Q2 | 3.33 Million USD | -7.32% |
| 2022 Q3 | 4.16 Million USD | 25.2% |
| 2022 Q4 | 4.49 Million USD | 7.84% |
| 2022 FY | 15.58 Million USD | 25.31% |
| 2022 Q1 | 3.59 Million USD | -62.17% |
| 2021 Q1 | 973 Thousand USD | -36.32% |
| 2021 Q4 | 9.49 Million USD | 1085.77% |
| 2021 FY | 12.44 Million USD | 108.1% |
| 2021 Q3 | 801 Thousand USD | -31.42% |
| 2021 Q2 | 1.16 Million USD | 20.04% |
| 2020 FY | 5.97 Million USD | 116.28% |
| 2020 Q1 | 1.79 Million USD | -16.02% |
| 2020 Q4 | 1.52 Million USD | 41.22% |
| 2020 Q3 | 1.08 Million USD | -31.08% |
| 2020 Q2 | 1.57 Million USD | -12.68% |
| 2019 Q4 | 2.14 Million USD | 681.39% |
| 2019 FY | 2.76 Million USD | 24.11% |
| 2019 Q3 | 274 Thousand USD | 48.91% |
| 2019 Q1 | 164 Thousand USD | -86.62% |
| 2019 Q2 | 184 Thousand USD | 12.2% |
| 2018 Q3 | 343 Thousand USD | 3.0% |
| 2018 Q1 | 325.07 Thousand USD | -98.9% |
| 2018 FY | 2.22 Million USD | -93.73% |
| 2018 Q2 | 333 Thousand USD | 2.44% |
| 2018 Q4 | 1.22 Million USD | 257.43% |
| 2017 Q2 | 590.29 Thousand USD | -88.37% |
| 2017 FY | 35.49 Million USD | 286.28% |
| 2017 Q4 | 29.56 Million USD | 11283.72% |
| 2017 Q3 | 259.73 Thousand USD | -56.0% |
| 2017 Q1 | 5.07 Million USD | 183.35% |
| 2016 Q1 | 1.03 Million USD | -28.27% |
| 2016 Q2 | 1.53 Million USD | 48.27% |
| 2016 Q4 | 1.79 Million USD | -62.94% |
| 2016 Q3 | 4.83 Million USD | 215.35% |
| 2016 FY | 9.18 Million USD | 112.83% |
| 2015 Q3 | 887.28 Thousand USD | -7.36% |
| 2015 Q1 | 1.03 Million USD | -47.9% |
| 2015 Q2 | 957.82 Thousand USD | -7.13% |
| 2015 FY | 4.31 Million USD | 54.76% |
| 2015 Q4 | 1.44 Million USD | 62.37% |
| 2014 Q2 | 347.9 Thousand USD | 94.62% |
| 2014 Q3 | 283.22 Thousand USD | -18.59% |
| 2014 Q1 | 178.76 Thousand USD | -67.7% |
| 2014 FY | 2.78 Million USD | 125.84% |
| 2014 Q4 | 1.97 Million USD | 598.93% |
| 2013 FY | 1.23 Million USD | -26.79% |
| 2013 Q4 | 553.5 Thousand USD | 284.56% |
| 2013 Q2 | 2.02 Million USD | 559.13% |
| 2013 Q1 | 307.51 Thousand USD | -24.01% |
| 2013 Q3 | -299.9 Thousand USD | -114.8% |
| 2012 FY | 1.68 Million USD | -51.62% |
| 2012 Q4 | 404.65 Thousand USD | 23.49% |
| 2012 Q3 | 327.69 Thousand USD | -25.69% |
| 2012 Q1 | 533.95 Thousand USD | -43.41% |
| 2012 Q2 | 440.99 Thousand USD | -17.41% |
| 2011 Q1 | 511.9 Thousand USD | -77.6% |
| 2011 Q3 | 1.09 Million USD | -19.56% |
| 2011 FY | 3.48 Million USD | 6.35% |
| 2011 Q4 | 943.57 Thousand USD | -13.95% |
| 2011 Q2 | 1.36 Million USD | 166.29% |
| 2010 FY | 3.27 Million USD | 511.53% |
| 2010 Q1 | 159.27 Thousand USD | 7.77% |
| 2010 Q2 | 174.46 Thousand USD | 9.54% |
| 2010 Q3 | 626.66 Thousand USD | 259.2% |
| 2010 Q4 | 2.28 Million USD | 264.68% |
| 2009 Q3 | 102.79 Thousand USD | -35.63% |
| 2009 Q2 | 159.69 Thousand USD | -17.26% |
| 2009 Q1 | 192.99 Thousand USD | 0.92% |
| 2009 Q4 | 147.78 Thousand USD | 43.77% |
| 2009 FY | 536.13 Thousand USD | -26.43% |
| 2008 Q2 | 172.44 Thousand USD | -1.43% |
| 2008 Q3 | 173.52 Thousand USD | 0.63% |
| 2008 Q1 | 174.94 Thousand USD | -4.29% |
| 2008 Q4 | 191.24 Thousand USD | 10.21% |
| 2008 FY | 728.73 Thousand USD | 8.04% |
| 2007 Q1 | 182.04 Thousand USD | -4.14% |
| 2007 Q3 | 160.03 Thousand USD | -4.27% |
| 2007 Q2 | 167.17 Thousand USD | -8.17% |
| 2007 Q4 | 182.77 Thousand USD | 14.21% |
| 2007 FY | 674.53 Thousand USD | -69.35% |
| 2006 Q1 | 1.09 Million USD | -70.04% |
| 2006 Q3 | 303.91 Thousand USD | -57.33% |
| 2006 FY | 2.2 Million USD | -49.53% |
| 2006 Q2 | 712.22 Thousand USD | -35.16% |
| 2006 Q4 | 189.9 Thousand USD | -37.51% |
| 2005 Q3 | 228.79 Thousand USD | -2.14% |
| 2005 FY | 4.35 Million USD | 307.1% |
| 2005 Q4 | 3.66 Million USD | 1502.38% |
| 2005 Q2 | 233.79 Thousand USD | -13.34% |
| 2005 Q1 | 269.8 Thousand USD | -69.25% |
| 2004 Q3 | 65.41 Thousand USD | -25.13% |
| 2004 FY | 1.07 Million USD | 371.79% |
| 2004 Q2 | 87.36 Thousand USD | 145.09% |
| 2004 Q4 | 877.37 Thousand USD | 1241.35% |
| 2004 Q1 | 35.64 Thousand USD | -22.13% |
| 2003 Q1 | 49.33 Thousand USD | -80.6% |
| 2003 Q4 | 45.77 Thousand USD | -45.43% |
| 2003 Q2 | 52.89 Thousand USD | 7.22% |
| 2003 FY | 226.98 Thousand USD | -68.08% |
| 2003 Q3 | 83.88 Thousand USD | 58.58% |
| 2002 Q2 | 74.15 Thousand USD | 5.02% |
| 2002 Q3 | 319.35 Thousand USD | 330.64% |
| 2002 FY | 711.15 Thousand USD | 61.51% |
| 2002 Q4 | 254.25 Thousand USD | -20.39% |
| 2002 Q1 | 70.61 Thousand USD | 61.11% |
| 2001 Q3 | 94.91 Thousand USD | 0.0% |
| 2001 FY | 440.31 Thousand USD | 1967.31% |
| 2001 Q4 | 43.83 Thousand USD | -53.82% |
| 2000 FY | 21.29 Thousand USD | -93.27% |
| 1999 FY | 316.47 Thousand USD | -18.77% |
| 1998 FY | 389.59 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Absci Corporation | 73.66 Million USD | 75.295% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 94.344% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 98.989% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -83.132% |
| Apollomics, Inc. | 54.14 Million USD | 66.385% |
| 180 Life Sciences Corp. | 13.47 Million USD | -35.032% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | 41.999% |
| Bicycle Therapeutics plc | 216.92 Million USD | 91.61% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 78.518% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 89.413% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | 61.284% |
| Chimerix, Inc. | 93.38 Million USD | 80.513% |
| CRISPR Therapeutics AG | 463.49 Million USD | 96.074% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | 46.042% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 84.372% |
| Fortress Biotech, Inc. | 200.19 Million USD | 90.909% |
| Fortress Biotech, Inc. | 200.19 Million USD | 90.909% |
| Gritstone bio, Inc. | 148.37 Million USD | 87.734% |
| Allakos Inc. | 196.05 Million USD | 90.717% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | 66.788% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 87.225% |
| Cytokinetics, Incorporated | 173.61 Million USD | 89.517% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | 29.693% |
| Innoviva, Inc. | 132.15 Million USD | 86.229% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -136.589% |
| NLS Pharmaceutics AG | 11.8 Million USD | -54.137% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 85.677% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -141043.167% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 82.255% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 79.521% |
| ImmuCell Corporation | 9.61 Million USD | -89.231% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 88.468% |
| Incyte Corporation | 1.19 Billion USD | 98.471% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 86.271% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -170.467% |
| Mustang Bio, Inc. | 48.5 Million USD | 62.477% |
| MiMedx Group, Inc. | 229.72 Million USD | 92.078% |
| MEI Pharma, Inc. | 34.78 Million USD | 47.681% |
| MacroGenics, Inc. | 217.21 Million USD | 91.622% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -106.075% |
| Mereo BioPharma Group plc | 35.84 Million USD | 49.224% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1.713% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 88.664% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 89.41% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | 21.178% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -14.56% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -76.947% |
| NextCure, Inc. | 67.63 Million USD | 73.093% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | 66.348% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | 38.529% |
| Onconetix, Inc. | 34.9 Million USD | 47.865% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -42.782% |
| Opthea Limited | 191.96 Million USD | 90.52% |
| Ovid Therapeutics Inc. | 59.67 Million USD | 69.502% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -561.401% |
| PDS Biotechnology Corporation | 43.04 Million USD | 57.721% |
| Precigen, Inc. | 84.18 Million USD | 78.381% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | 74.921% |
| Prime Medicine, Inc. | 186.63 Million USD | 90.249% |
| PureTech Health plc | 144.59 Million USD | 87.414% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 92.991% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.354% |
| Replimune Group, Inc. | 234.77 Million USD | 92.248% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -110.231% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 86.029% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | 6.28% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 96.351% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 25.127% |
| Sesen Bio, Inc. | 78.38 Million USD | 76.781% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 92.042% |
| Solid Biosciences Inc. | 104.31 Million USD | 82.554% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 92.086% |
| SciSparc Ltd. | 9.01 Million USD | -101.964% |
| Sutro Biopharma, Inc. | 243 Million USD | 92.511% |
| TG Therapeutics, Inc. | 198.47 Million USD | 90.831% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 85.01% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -143.922% |
| Travere Therapeutics, Inc. | 472 Million USD | 96.144% |
| UroGen Pharma Ltd. | 138.88 Million USD | 86.897% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | 74.22% |
| XOMA Corporation | 46.46 Million USD | 60.831% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 92.794% |
| AbCellera Biologics Inc. | 275.23 Million USD | 93.388% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | 67.936% |
| Cassava Sciences, Inc. | 105.95 Million USD | 82.824% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -30.837% |
| Precision BioSciences, Inc. | 92.46 Million USD | 80.318% |
| Dyadic International, Inc. | 9.15 Million USD | -98.838% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -118.764% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | 18.218% |
| VYNE Therapeutics Inc. | 29.68 Million USD | 38.687% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 86.128% |
| IGM Biosciences, Inc. | 265.59 Million USD | 93.148% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 83.074% |
| Acelyrin, Inc. | 422.06 Million USD | 95.688% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1.449% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 78.418% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -170.338% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 92.572% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | 40.857% |
| Senti Biosciences, Inc. | 94.7 Million USD | 80.783% |
| Mesoblast Limited | 5.9 Million USD | -208.353% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 92.545% |
| ChromaDex Corporation | 56.37 Million USD | 67.72% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | 45.398% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 90.951% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -126.302% |
| Seer, Inc. | 110.49 Million USD | 83.529% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 89.195% |
| Novavax, Inc. | 779.12 Million USD | 97.664% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -15.993% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 92.836% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | 65.17% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 92.636% |
| Celcuity Inc. | 66.23 Million USD | 72.522% |
| ContextLogic Inc. | 387 Million USD | 95.297% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 89.156% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | 44.424% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 99.441% |
| Amarin Corporation plc | 272.35 Million USD | 93.318% |
| AnaptysBio, Inc. | 181.56 Million USD | 89.977% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | 36.98% |
| Aptorum Group Limited | 10.56 Thousand USD | -172141.151% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 83.585% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 95.917% |
| Ardelyx, Inc. | 169.93 Million USD | 89.291% |
| Celularity Inc. | 215.05 Million USD | 91.538% |
| Omeros Corporation | 94.75 Million USD | 80.793% |
| Humacyte, Inc. | 23.49 Million USD | 22.548% |
| Immunocore Holdings plc | 308.04 Million USD | 94.092% |
| IO Biotech, Inc. | 91.44 Million USD | 80.098% |
| GT Biopharma, Inc. | 13.57 Million USD | -34.053% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 75.624% |
| Summit Therapeutics Inc. | 87.68 Million USD | 79.245% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | 38.244% |
| Pulmatrix, Inc. | 22.03 Million USD | 17.42% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 96.7% |
| Evogene Ltd. | 27.79 Million USD | 34.512% |
| CorMedix Inc. | 48.95 Million USD | 62.827% |
| BioLineRx Ltd. | 50.8 Million USD | 64.177% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | 46.607% |
| Sagimet Biosciences Inc. | 32.74 Million USD | 44.414% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 98.613% |
| scPharmaceuticals Inc. | 65.17 Million USD | 72.078% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 83.961% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 95.063% |
| NLS Pharmaceutics AG | 11.8 Million USD | -54.137% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | 25.127% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 89.472% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | 51.35% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | 29.209% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 85.27% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 78.087% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | 65.744% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -115.303% |
| Daré Bioscience, Inc. | 33.6 Million USD | 45.851% |
| bluebird bio, Inc. | 240.23 Million USD | 92.424% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 98.958% |
| DBV Technologies S.A. | 92.16 Million USD | 80.253% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 92.577% |
| Galecto, Inc. | 35.62 Million USD | 48.918% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | 50.898% |
| Spruce Biosciences, Inc. | 62.08 Million USD | 70.686% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 91.721% |
| GlycoMimetics, Inc. | 39.28 Million USD | 53.675% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 93.846% |
| ADMA Biologics, Inc. | 66.58 Million USD | 72.668% |
| Clene Inc. | 41.07 Million USD | 55.691% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 94.831% |
| Aptose Biosciences Inc. | 52.35 Million USD | 65.24% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -26.291% |
| Soligenix, Inc. | 7.79 Million USD | -133.463% |
| Century Therapeutics, Inc. | 56.07 Million USD | 67.543% |
| Kura Oncology, Inc. | 165.8 Million USD | 89.024% |
| Surrozen, Inc. | 18.55 Million USD | 1.892% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 84.107% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -633.346% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 83.102% |
| Autolus Therapeutics plc | 196.72 Million USD | 90.749% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 78.503% |
| Eterna Therapeutics Inc. | 19.38 Million USD | 6.108% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 87.911% |
| GRI Bio, Inc. | 11.33 Million USD | -60.627% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -157.933% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 77.549% |
| INmune Bio, Inc. | 29.89 Million USD | 39.126% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 89.453% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 54.857% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -13.891% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -121.024% |
| Jaguar Health, Inc. | 42.01 Million USD | 56.685% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -15.611% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | 70.693% |
| Clearside Biomedical, Inc. | 32.71 Million USD | 44.371% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 93.399% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 93.963% |
| Verastem, Inc. | 92.08 Million USD | 80.237% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 90.201% |
| Histogen Inc. | 14.27 Million USD | -27.515% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -13.403% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 97.587% |
| Surrozen, Inc. | 18.55 Million USD | 1.892% |
| Organovo Holdings, Inc. | 14.91 Million USD | -22.018% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -257.528% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -138.43% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 89.784% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | 62.436% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -18.432% |
| Kronos Bio, Inc. | 128.11 Million USD | 85.795% |
| Turnstone Biologics Corp. | 78.33 Million USD | 76.769% |
| Synaptogenix, Inc. | 8.31 Million USD | -118.9% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -24.77% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 86.231% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 92.808% |
| Exelixis, Inc. | 1.58 Billion USD | 98.853% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 92.157% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 97.872% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 73.571% |
| ESSA Pharma Inc. | 32.13 Million USD | 43.365% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -11.239% |
| Avid Bioservices, Inc. | 25.99 Million USD | 29.993% |
| Insmed Incorporated | 949.26 Million USD | 98.083% |
| MediWound Ltd. | 18.86 Million USD | 3.546% |
| OmniAb, Inc. | 83.89 Million USD | 78.307% |
| Alector, Inc. | 248.8 Million USD | 92.685% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 92.233% |
| Zai Lab Limited | 547.47 Million USD | 96.676% |
| AlloVir, Inc. | 180.93 Million USD | 89.942% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 95.435% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 83.572% |
| Aura Biosciences, Inc. | 84.99 Million USD | 78.587% |
| Immunic, Inc. | 99.22 Million USD | 81.658% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 88.555% |
| Veracyte, Inc. | 357.93 Million USD | 94.916% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.798% |
| FibroGen, Inc. | 398.11 Million USD | 95.429% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -28.072% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 92.985% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -164.215% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -155.398% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | 29.66% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 94.251% |
| Fortrea Holdings Inc. | 457.3 Million USD | 96.02% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | 66.471% |
| XBiotech Inc. | 37.51 Million USD | 51.482% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 73.571% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 89.249% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | 51.942% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | 11.865% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 87.189% |
| Agenus Inc. | 78.18 Million USD | 76.723% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 81.631% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 83.562% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 98.101% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | 36.908% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 95.774% |
| Gain Therapeutics, Inc. | 22.3 Million USD | 18.421% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 88.61% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -229.039% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | 28.516% |
| Lantern Pharma Inc. | 17.87 Million USD | -1.798% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | 57.677% |
| Ainos, Inc. | 12.95 Million USD | -40.504% |
| Pluri Inc. | 22.48 Million USD | 19.044% |
| Prothena Corporation plc | 282.4 Million USD | 93.556% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 90.902% |
| Rallybio Corporation | 78.93 Million USD | 76.943% |
| Kodiak Sciences Inc. | 277.32 Million USD | 93.438% |
| Cue Biopharma, Inc. | 19.54 Million USD | 6.872% |
| MeiraGTx Holdings plc | 151.07 Million USD | 87.954% |
| Annexon, Inc. | 143.72 Million USD | 87.337% |
| Assembly Biosciences, Inc. | 22.9 Million USD | 20.56% |
| Moderna, Inc. | 6.39 Billion USD | 99.715% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -436.844% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 79.049% |
| Blueprint Medicines Corporation | 722.86 Million USD | 97.482% |
| Immix Biopharma, Inc. | 16.14 Million USD | -12.749% |
| CalciMedica, Inc. | 21.81 Million USD | 16.583% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 87.301% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 89.376% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 89.962% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 93.83% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | 47.364% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | 74.916% |
| Nutriband Inc. | 5.73 Million USD | -217.386% |
| Protara Therapeutics, Inc. | 43.61 Million USD | 58.272% |
| Vor Biopharma Inc. | 126.03 Million USD | 85.56% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 98.47% |
| Alkermes plc | 996.24 Million USD | 98.173% |
| ProKidney Corp. | 151.52 Million USD | 87.989% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 75.465% |
| Arcellx, Inc. | 200.19 Million USD | 90.91% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 97.037% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 87.924% |
| Galectin Therapeutics Inc. | 38.07 Million USD | 52.198% |
| Atai Life Sciences N.V. | 125.78 Million USD | 85.532% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 77.708% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 77.645% |
| MediciNova, Inc. | 10.9 Million USD | -66.959% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 85.873% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -150.691% |
| GeoVax Labs, Inc. | 6.02 Million USD | -202.2% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 96.18% |
| Biomea Fusion, Inc. | 126.13 Million USD | 85.572% |
| RenovoRx, Inc. | 11.39 Million USD | -59.696% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 90.476% |
| Geron Corporation | 70.44 Million USD | 74.164% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 34.019% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 86.377% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 92.485% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 93.055% |
| Royalty Pharma plc | 862.4 Million USD | 97.89% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 91.25% |
| Imunon, Inc. | 20.31 Million USD | 10.396% |
| BioAtla, Inc. | 129.68 Million USD | 85.967% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 78.569% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | 56.418% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 91.243% |
| Structure Therapeutics Inc. | 102.77 Million USD | 82.292% |
| 89bio, Inc. | 151.2 Million USD | 87.964% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 83.63% |
| aTyr Pharma, Inc. | 12.97 Million USD | -40.219% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 82.443% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 92.857% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -121.269% |
| Akari Therapeutics, Plc | 16.8 Million USD | -8.289% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -700.318% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 93.92% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 89.472% |
| Liquidia Corporation | 87.98 Million USD | 79.316% |
| Entera Bio Ltd. | 8.86 Million USD | -105.406% |
| GH Research PLC | 41.22 Million USD | 55.851% |
| Vericel Corporation | 142.04 Million USD | 87.187% |
| Arbutus Biopharma Corporation | 22.54 Million USD | 19.273% |
| Xencor, Inc. | 306.97 Million USD | 94.072% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -268.878% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -13.891% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | 11.181% |
| Vaxcyte, Inc. | 468.04 Million USD | 96.112% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | 60.898% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 90.511% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -170.467% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -150.691% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 82.661% |
| OncoCyte Corporation | 25.63 Million USD | 29.013% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -198.559% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -58.845% |
| Purple Biotech Ltd. | -22.46 Million USD | 181.003% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | 37.583% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | 41.025% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 92.792% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -10.431% |
| Moleculin Biotech, Inc. | 29.63 Million USD | 38.581% |
| United Therapeutics Corporation | 885.1 Million USD | 97.944% |
| HilleVax, Inc. | 133.34 Million USD | 86.352% |
| Silo Pharma, Inc. | 3.92 Million USD | -364.04% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -361.664% |
| Pharming Group N.V. | 225.49 Million USD | 91.929% |
| Tharimmune, Inc. | 9.45 Million USD | -92.476% |
| Genprex, Inc. | 31.06 Million USD | 41.408% |
| Apogee Therapeutics, Inc. | 93 Million USD | 80.432% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 90.295% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 77.859% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -2278.954% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -234.115% |
| OKYO Pharma Limited | 8243.57 USD | -220666.003% |
| Savara Inc. | 15.74 Million USD | -15.586% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -4.25% |
| Curis, Inc. | 58.35 Million USD | 68.813% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -257.37% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | 32.651% |
| BeiGene, Ltd. | 3.28 Billion USD | 99.446% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 88.156% |
| Erasca, Inc. | 141.52 Million USD | 87.141% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -302.012% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -302.012% |
| Vincerx Pharma, Inc. | 42.6 Million USD | 57.288% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -26.681% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | 72.716% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | 58.08% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 91.256% |
| Adicet Bio, Inc. | 152.03 Million USD | 88.03% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 95.744% |
| Aditxt, Inc. | 25.95 Million USD | 29.871% |
| Adagene Inc. | 41.83 Million USD | 56.494% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -148.957% |
| Quantum-Si incorporated | 111.65 Million USD | 83.701% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -24.841% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | 49.196% |
| Compugen Ltd. | 43.97 Million USD | 58.611% |
| Generation Bio Co. | 144.46 Million USD | 87.403% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 78.081% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 78.951% |
| Invivyd, Inc. | 205.75 Million USD | 91.155% |
| Relay Therapeutics, Inc. | 72.15 Million USD | 74.779% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -94.05% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 75.817% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -76.913% |
| 2seventy bio, Inc. | 289.88 Million USD | 93.722% |
| Instil Bio, Inc. | 85.78 Million USD | 78.785% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -42.092% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -1504.03% |
| GeoVax Labs, Inc. | 6.02 Million USD | -202.2% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | 50.455% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 82.451% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 89.312% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 97.629% |
| Evaxion Biotech A/S | 22.27 Million USD | 18.28% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 86.573% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 92.252% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 77.236% |
| Cingulate Inc. | 22.75 Million USD | 20.037% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 342.912% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 59.256% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | 70.682% |
| Clearmind Medicine Inc. | 8.74 Million USD | -108.194% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 78.353% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -520.494% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 81.95% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 95.217% |
| ImmunityBio, Inc. | 362.87 Million USD | 94.985% |
| Korro Bio, Inc. | 84.53 Million USD | 78.471% |
| Kineta, Inc. | 21.15 Million USD | 13.977% |
| BioVie Inc. | 31.95 Million USD | 43.039% |
| Codexis, Inc. | 66.51 Million USD | 72.64% |
| Celularity Inc. | 215.05 Million USD | 91.538% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -11.815% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 91.969% |
| Virax Biolabs Group Limited | 6.54 Million USD | -177.972% |
| Cibus, Inc. | 320.3 Million USD | 94.318% |
| IN8bio, Inc. | 30.33 Million USD | 40.011% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 85.736% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -2743.594% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 97.666% |
| Eyenovia, Inc. | 25.4 Million USD | 28.369% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 87.03% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -227.202% |
| Elevation Oncology, Inc. | 45.44 Million USD | 59.954% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 77.002% |
| Cardiff Oncology, Inc. | 45.9 Million USD | 60.351% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 91.591% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -82.776% |
| Moolec Science SA | 52.75 Million USD | 65.5% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | 70.233% |
| LAVA Therapeutics N.V. | 46.54 Million USD | 60.896% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 80.654% |
| Compass Therapeutics, Inc. | 48.47 Million USD | 62.455% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -95.104% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | 19.575% |
| Humacyte, Inc. | 23.49 Million USD | 22.548% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 77.289% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -25.165% |
| Genelux Corporation | 24.33 Million USD | 25.215% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | 46.352% |
| Notable Labs, Ltd. | 14.77 Million USD | -23.216% |
| Immunovant, Inc. | 282.7 Million USD | 93.563% |
| Quantum-Si incorporated | 111.65 Million USD | 83.701% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | 14.426% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 82.16% |
| Acasti Pharma Inc. | 11.3 Million USD | -61.039% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | 20.602% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | 56.024% |
| PepGen Inc. | 84.76 Million USD | 78.53% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | 20.518% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | 44.389% |
| Immuneering Corporation | 58.41 Million USD | 68.844% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -257.528% |
| Belite Bio, Inc | 31.66 Million USD | 42.532% |
| XOMA Corporation | 46.46 Million USD | 60.831% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | 73.058% |
| Bionomics Limited | 17.89 Billion USD | 99.898% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 151.006% |
| uniQure N.V. | 285.08 Million USD | 93.616% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -148.957% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 90.629% |
| Forte Biosciences, Inc. | 32.47 Million USD | 43.963% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -119.034% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | 38.088% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -227.202% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -28.072% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -104.736% |
| Altimmune, Inc. | 30.55 Million USD | 40.441% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | 74.26% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 151.006% |
| Peak Bio, Inc. | 1249.13 USD | -1456834.026% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 75.447% |
| Benitec Biopharma Inc. | 22.38 Million USD | 18.689% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 92.517% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | 36.24% |
| Zura Bio Limited | 62.63 Million USD | 70.946% |
| PolyPid Ltd. | 21.04 Million USD | 13.523% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | 36.24% |
| argenx SE | 1.53 Billion USD | 98.813% |
| Immunome, Inc. | 122.82 Million USD | 85.182% |
| Verona Pharma plc | 67.15 Million USD | 72.899% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | 29.693% |
| Shattuck Labs, Inc. | 93.61 Million USD | 80.56% |
| CervoMed Inc. | 14.95 Million USD | -21.669% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -113.003% |
| Dianthus Therapeutics, Inc. | 51 Million USD | 64.316% |
| Moolec Science SA | 52.75 Million USD | 65.5% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -10.643% |
| Design Therapeutics, Inc. | 78.19 Million USD | 76.725% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 79.091% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -44.609% |
| Achilles Therapeutics plc | 75.25 Million USD | 75.817% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -520.494% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | 67.299% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | 64.231% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | 72.467% |
| MoonLake Immunotherapeutics | 54.12 Million USD | 66.375% |
| Tourmaline Bio, Inc. | 45.4 Million USD | 59.922% |
| Beam Therapeutics Inc. | 554.19 Million USD | 96.716% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 92.676% |
| AEON Biopharma, Inc. | 48.42 Million USD | 62.421% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 80.531% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 78.212% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -44.587% |
| NeurAxis, Inc. | 8.82 Million USD | -106.31% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 95.965% |
| Lumos Pharma, Inc. | 38.66 Million USD | 52.932% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | 31.331% |
| Palisade Bio, Inc. | 13.32 Million USD | -36.629% |
| Nutriband Inc. | 5.73 Million USD | -217.386% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 79.293% |
| Neurogene Inc. | 55.58 Million USD | 67.258% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -115.347% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 81.182% |
| Athira Pharma, Inc. | 125.46 Million USD | 85.495% |
| HCW Biologics Inc. | 21.02 Million USD | 13.452% |
| XOMA Corporation | 46.46 Million USD | 60.831% |
| Nektar Therapeutics | 190.9 Million USD | 90.467% |
| Arvinas, Inc. | 480 Million USD | 96.209% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -700.318% |
| Merus N.V. | 200.49 Million USD | 90.923% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 82.392% |
| Quince Therapeutics, Inc. | 34.62 Million USD | 47.432% |
| Rezolute, Inc. | 70.38 Million USD | 74.144% |
| Clene Inc. | 41.07 Million USD | 55.691% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -11.115% |
| BeyondSpring Inc. | 24.86 Million USD | 26.809% |
| Synlogic, Inc. | 58.53 Million USD | 68.908% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1.716% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -305.142% |
| Peak Bio, Inc. | 1249.13 USD | -1456834.026% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | 69.892% |
| Krystal Biotech, Inc. | 160.42 Million USD | 88.656% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 93.275% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 94.771% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -743.822% |
| MannKind Corporation | 125.59 Million USD | 85.51% |
| Ikena Oncology, Inc. | 84.57 Million USD | 78.482% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -88.649% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 79.689% |
| Gossamer Bio, Inc. | 183.75 Million USD | 90.096% |
| CohBar, Inc. | 12.38 Million USD | -46.905% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | 64.122% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | 34.019% |
| Legend Biotech Corporation | 583.14 Million USD | 96.879% |
| Mural Oncology plc | 192.07 Million USD | 90.525% |
| Disc Medicine, Inc. | 91.12 Million USD | 80.029% |
| Champions Oncology, Inc. | 28.11 Million USD | 35.258% |
| REGENXBIO Inc. | 321.15 Million USD | 94.333% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -239.455% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 67.36% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | 53.289% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 84.086% |
| Vaxart, Inc. | 90.72 Million USD | 79.941% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -113.603% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | 57.473% |
| Cellectis S.A. | 97.32 Million USD | 81.3% |
| Longeveron Inc. | 21.25 Million USD | 14.358% |
| Repare Therapeutics Inc. | 167.35 Million USD | 89.126% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 98.663% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 75.942% |
| Revolution Medicines, Inc. | 498.76 Million USD | 96.351% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -173.587% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | 58.595% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 75.601% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | 73.865% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -64.548% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.619% |
| Denali Therapeutics Inc. | 527.23 Million USD | 96.548% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -110.231% |
| Veru Inc. | 101.34 Million USD | 82.043% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | 22.25% |
| Cingulate Inc. | 22.75 Million USD | 20.037% |
| Passage Bio, Inc. | 108.38 Million USD | 83.21% |
| Context Therapeutics Inc. | 25.07 Million USD | 27.415% |
| Exicure, Inc. | 14.07 Million USD | -29.291% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 91.168% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | 57.971% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -98.305% |
| Nuvalent, Inc. | 149.49 Million USD | 87.826% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -125.601% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 82.442% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | 15.152% |
| OmniAb, Inc. | 83.89 Million USD | 78.307% |
| Anew Medical, Inc. | 1.3 Million USD | -1299.018% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | 44.454% |
| Lipocine Inc. | 15.08 Million USD | -20.682% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | 73.437% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 76.102% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 54.857% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 84.153% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | 18.696% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 97.26% |
| Ocugen, Inc. | 71.56 Million USD | 74.571% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 80.612% |
| Q32 Bio Inc. | 92.68 Million USD | 80.364% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | 14.05% |
| Alumis Inc. Common Stock | 158.17 Million USD | 88.494% |
| Equillium, Inc. | 50.6 Million USD | 64.038% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | 70.838% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -30.876% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | 3.531% |
| Dominari Holdings Inc. | 23.83 Million USD | 23.646% |
| Edesa Biotech, Inc. | 9.22 Million USD | -97.327% |
| vTv Therapeutics Inc. | 11.9 Million USD | -52.843% |
| Bio-Techne Corporation | 563.03 Million USD | 96.768% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 95.548% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 93.228% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 86.242% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -26.285% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 88.882% |
| Nkarta, Inc. | 131.65 Million USD | 86.176% |
| BioCardia, Inc. | 12.12 Million USD | -50.144% |
| Iterum Therapeutics plc | 47.46 Million USD | 61.66% |